In the treatment of mice bearing subcutaneous and intraperitoneal advanced ovarian cancer tumors (SKOV3 and OVCAR8), AZ7379 incorporated in PTP liposomes profoundly enhanced PARP inhibition, leading to deceleration of tumor growth and a 3-fold and 1.7-fold decrease in tumor volumes [66]. Here, PARP1 is linked to neoplasm.